What does this research mean for the field?

Amivantamab demonstrates significant antitumor activity, achieving a 42% objective response rate, and a manageable safety profile in patients with recurrent/metastatic head and neck squamous cell carcinoma previously treated with checkpoint inhibitors and chemotherapy. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aimed to evaluate the effectiveness of amivantamab in recurrent/metastatic head and neck squamous cell cancer after prior treatments.

June 2, 2026Open Access

Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 study

Puntos clave

The study aimed to evaluate the effectiveness of amivantamab in recurrent/metastatic head and neck squamous cell cancer after prior treatments.
Cohort 1 of OrigAMI-4 (NCT06385080) administered amivantamab subcutaneously every three weeks to 102 participants.
Primary endpoint was objective response rate (ORR) assessed by independent review; secondary endpoints included PFS and OS.
Participants had prior exposure to PD-(L)1 inhibitors and platinum-based chemotherapy, excluding those previously treated with anti-EGFR.
Blinded review assessed ORR was 42% (95% CI, 32-52) with a complete response rate of 15%.
Median PFS was 6.8 months (95% CI, 5.2-8.3) and median OS was 12.5 months (95% CI, 10.2-16.8).
Investigator-assessed ORR was 47% (95% CI, 37-57) and adverse events were consistent with prior knowledge.

Resumen

Single-agent paclitaxel or cetuximab after immune checkpoint inhibitor (ICI) and chemotherapy demonstrated objective response rates (ORRs) of 21%-24% in recurrent/metastatic (R/M) head/neck squamous cell cancer (HNSCC). EGFR and MET are overexpressed in R/M HNSCC. Amivantamab, an EGFR-MET bispecific antibody, may be a rational treatment. Cohort 1 of OrigAMI-4 (NCT06385080) evaluated subcutaneous amivantamab administered every three weeks in participants with R/M HNSCC after PD-(L)1 inhibitor and platinum-based chemotherapy. Prior anti-EGFR was exclusionary. The primary endpoint was RECIST v1.1 ORR. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. In 102 participants, blinded independent central review-assessed ORR was 42% (95% CI, 32-52); the complete response rate was 15%. Median DoR was not reached (NR; 95% CI, 6.9-NR); 56% of responses lasted ≥6 months. Investigator-assessed ORR was 47% (95% CI, 37-57). At a median follow-up of 11.8 months (range, 1.1-21.9), median PFS and OS were 6.8 months (95% CI, 5.2-8.3) and 12.5 months (95% CI, 10.2-16.8), respectively. Adverse events were consistent with previous experience with no new safety signals. Treatment-related discontinuations were low (8%). Amivantamab demonstrated greater antitumor activity in participants previously exposed to ICI and chemotherapy than what has been reported for paclitaxel or cetuximab.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo